Immediate early protein 1 (IE1) (IE1)

The Human cytomegalovirus 72-kD immediate early protein (IE1), encoded by the UL123 gene, is the first viral protein synthesized following infection and is essential for the efficient initiation of the viral lytic cycle. It serves as a master transcriptional transactivator, modulating both viral and host gene expression to create an environment conducive to viral replication. One of its most critical roles is the evasion of the host's innate immune system, achieved by disrupting Promyelocytic Leukemia (PML) nuclear bodies and antagonizing the type I interferon response. In the context of human health, IE1 is a major determinant of HCMV pathogenesis in immunocompromised individuals and a leading cause of congenital abnormalities when transmitted in utero. Because of its early expression and high immunogenicity, IE1 is a primary target for next-generation vaccines and adoptive T-cell therapies aimed at controlling CMV reactivation in transplant recipients. While current frontline antivirals target the viral DNA polymerase, IE1 represents a strategic target for early-intervention therapies that aim to halt the infection before significant viral shedding or tissue damage occurs.

Other names

Human cytomegalovirus 72-kD immediate early proteinIE72UL123Major immediate-early protein 1pp72

Experimental vaccines and immunotherapies target IE1 to induce cytotoxic T-lymphocyte (CTL) responses that recognize and eliminate CMV-infected cells during the earliest stages of the viral lytic cycle. Research into small molecules focuses on inhibiting the protein's ability to transactivate viral genes or its capacity to disrupt PML nuclear bodies, thereby preventing the initiation of viral replication.